Myths and fallacies in permanent prostate brachytherapy

Area of Science:

• Oncology
• Radiation Oncology
• Urology

Background:

• Competing treatment modalities for early-stage prostate cancer exist, including surgery and external beam therapy.
• Constraints from these modalities are sometimes incorrectly applied to brachytherapy.
• Understanding the origin of these constraints allows for their circumvention in brachytherapy.

Purpose of the Study:

• To address and correct the misapplication of treatment constraints from surgery and external beam therapy to prostate brachytherapy.
• To highlight how knowledge of constraint mechanisms can overcome perceived limitations in brachytherapy.
• To demonstrate methods for improving brachytherapy outcomes and reducing associated morbidities.

Main Methods:

• Analyzing historical data and perceived limitations of prostate brachytherapy.
• Identifying specific parameters (patient age, weight, prostate size, histology) and their relevance to different treatment modalities.
• Examining failure patterns, such as extracapsular disease extension, and their relationship to biopsy results and Gleason score.
• Investigating dosimetric control strategies for the urethra and penile bulb.

Main Results:

• Perceived limitations of brachytherapy based on patient factors are often misapplied from other modalities.
• Extracapsular disease extension, indicated by high positive biopsy rates or Gleason score, can be managed with consistent extracapsular dosimetric margins.
• Urinary morbidity and sexual dysfunction can be minimized by precise dosimetry around the urethra and penile bulb.

Conclusions:

• Brachytherapy for early-stage prostate cancer can overcome limitations erroneously attributed to it.
• Consistent extracapsular dosimetric margins are crucial for preventing treatment failures due to disease extension.
• Optimized dosimetry offers a means to significantly reduce urinary and sexual side effects, enhancing quality of life.